| Literature DB >> 33125685 |
Ross Ka-Kit Leung1,2, Yixin Lin3,4, Yanhui Liu3,4.
Abstract
Intrauterine adhesion is a major cause of menstrual irregularities, infertility, and recurrent pregnancy losses and the progress towards its amelioration and therapy is slow and unsatisfactory. We aim to summarize and evaluate the current treatment progress and research methods for intrauterine adhesion. We conducted literature review in January 2020 by searching articles at PubMed on prevention and treatment, pathogenesis, the repair of other tissues/organs, cell plasticity, and the stem cell-related therapies for intrauterine adhesion. A total of 110 articles were selected for review. Uterine cell heterogeneity, expression profile, and cell-cell interaction were investigated based on scRNA-seq of uterus provided by Human Cell Landscape (HCL) project. Previous knowledge on intrauterine adhesion (IUA) pathogenesis was mostly derived from correlation studies by differentially expressed genes between endometrial tissue of intrauterine adhesion patients/animal models and normal endometrial tissue. Although the TGF-β1/SMAD pathway was suggested as the key driver for IUA pathogenesis, uterine cell heterogeneity and distinct expression profile among different cell types highlighted the importance of single-cell investigations. Cell-cell interaction in the uterus revealed the central hub of endothelial cells interacting with other cells, with endothelial cells in endothelial to mesenchymal transition and fibroblasts as the strongest interaction partners. The potential of stem cell-related therapies appeared promising, yet suffers from largely animal studies and nonstandard study design. The need to dissect the roles of endometrial cells, endothelial cells, and fibroblasts and their interaction is evident in order to elucidate the molecular and cellular mechanisms in both intrauterine adhesion pathogenesis and treatment.Entities:
Keywords: Cell heterogeneity; Cell-cell interaction; Intrauterine adhesion (IUA); Molecular mechanism; TGF-β1/SMAD pathway
Mesh:
Substances:
Year: 2020 PMID: 33125685 PMCID: PMC8189970 DOI: 10.1007/s43032-020-00343-y
Source DB: PubMed Journal: Reprod Sci ISSN: 1933-7191 Impact factor: 3.060
Fig. 1Mainstream methodology for the current research in IUA pathogenesis
Fig. 2Potential molecular mediators involved in IUA pathogenesis
Summary of previous work on IUA pathogenesis
| Species | Tissue | Sample size | Cell line/cell model | Molecules/pathways associated with IUA pathogenesis | References | |
|---|---|---|---|---|---|---|
| Human | Animal model | |||||
| Human; rabbit | Blood/uterine tissue | 60 patients and 30 fertile women | 18 IUA rabbit models and 18 mature female fertile rabbits | – | Smad3; Smad7; TGF-β1 | [ |
| Human; rat | Endometrial tissue | 40 intrauterine adhesion tissues and 20 normal endometrium tissues | 30 IUA rats (phenol mucilage treatment), 15 rats for sham group (with mock treatment), and 15 rats for normal group (with no treatment) | – | NF-κB | [ |
| Human; rat | Endometrial tissue | 92 patients and 86 women in control group | 50 rats were divided into control group, sham group, model group, NC-siRNA group, and KDR-siRNA group, with 10 rats in each group | – | KDR; TGF-β1/SMAD pathway; MMP-9 | [ |
| Human; mouse | Women endometrial tissue; mouse uterine horns | 19 women with IUA and 16 disease-free women as control group | Not indicated | – | SOX2; NANOG; OCT4 | [ |
| Rat | Endometrial tissue | – | 6 rats in IUA group and 6 in sham group | – | TGF-β1/BMP7/SMAD pathway; epithelial-mesenchymal transition (EMT) | [ |
| Human; rat | Endometrial tissue | 76 IUA patients and 20 samples of normal endometrium | 70 rats in experimental group and 10 in control group | – | TGF-β1; MMP-9; ERα; SDF-1/CXCR-4 axis | [ |
| Rat | Endometrial tissue | 12 rat IUA models, 4 rats in sham-operated group, and 4 in control group | – | – | miR-29b; Sp1/TGF-β1/SMAD-CTGF | [ |
| Human | Endometrial tissue | 3 patients with severe IUA (the sample size of normal endometrium was not indicated) | – | – | miR-513a-5p; miR-135a-3p; miR-543; N-cadherin; collagen 16A1; ADAM9; lysyl oxidase | [ |
| Human; mouse | Endometrial tissue | 39 patients with IUAs and 28 normal control cases | 12 mice were divided into three groups: IUAs ( | – | miR-1291; ArhGAP29; RhoA/ROCK1 EMT pathway | [ |
| Human | Endometrial tissue | Not indicated | – | Primary endometrial stromal cells (ESCs) | miR-29b; TGF-β1/SMAD pathway | [ |
| Human | Endometrial tissue | 70 endometrium tissue from IUA patients, 15 from patients with uterine septum, and 15 normal endometrium | – | RL95–2 | TGF-β; CCN2; NF-κB pathway | [ |
| Human | Endometrial tissue | 30 endometrial tissues from IUA patients and 15 normal endometrial tissues | – | Primary endometrial stromal cells (ESCs) | miRNA-326; TGF-β1/Smad3 | [ |
Fig. 3Various cell types in uterus. cluster1: endothelial cell_COL15A1 high; cluster2: endothelial cell_ESM1 high; cluster3: endothelial cell_IL6 high; cluster4: endothelial cell_SOCS3 high; cluster5: smooth muscle cell_MYL9 high; cluster6: stromal cell_RGS5 high; cluster7: fibroblast; cluster8: smooth muscle cell_PDK4 high; cluster9: smooth muscle cell_ACTG2 high; cluster10: stromal cell_ERRFI1 high; cluster11: endometrial cell; cluster12: M1 Macrophage; cluster13: T cell; cluster14: endothelial cell in EMT; cluster15: endothelial cell_FABP4 high; cluster16: Mast cell; cluster17: luminal epithelium
Fig. 4Uterine cellular expression profile related to IUA pathogenesis. cluster1: endothelial cell_COL15A1 high; cluster2: endothelial cell_ESM1 high; cluster3: endothelial cell_IL6 high; cluster4: endothelial cell_SOCS3 high; cluster5: smooth muscle cell_MYL9 high; cluster6: stromal cell_RGS5 high; cluster7: fibroblast; cluster8: smooth muscle cell_PDK4 high; cluster9: smooth muscle cell_ACTG2 high; cluster10: stromal cell_ERRFI1 high; cluster11: endometrial cell; cluster12: M1 macrophage; cluster13: T cell; cluster14: endothelial cell in EMT; cluster15: endothelial cell_FABP4 high; cluster16: mast cell; cluster17: luminal epithelium
Molecules and signaling pathways associated with differentiation and transdifferentiation
| Pathway | Activation/inhibition | Starting cell and ending cells | Remarks | References |
|---|---|---|---|---|
| Notch | Inhibition | Mouse fibroblast → cardiomyocytes | – | [ |
| JAK-STAT | Activation | Mouse neural stem cells/fibroblasts → iPSCs | – | [ |
| Inhibition | Mouse embryonic fibroblasts → cardiomyocytes | With expression of OSKM and Bmp4 | [ | |
| TGF-β | Inhibition | Mouse embryonic fibroblasts → iPSCs | – | [ |
| Mesenchymal-type human fibroblasts → iPSCs | – | [ | ||
| BMP | Activation | Mouse fibroblasts → cardiovascular progenitor cells (CPC) | With activation of Wnt and TGF-β pathway | [ |
| Wnt | Activation | Mouse fibroblasts/neural stem cells → iPSCs | – | [ |
| Inhibition | Mouse fibroblasts → cardiomyocyte | With SB431542 | [ | |
| Activated by CHIR99021 | Mouse fibroblasts → cardiomyocyte | With Repsox (inhibiting TGF-β signaling), forskolin (increasing cAMP), and phosphodiesterase (PDE) 4 inhibitors (rolipram and cilomilast) | [ | |
| Human fibroblasts → neurons | With inhibition of TGF-β signaling by SB431542 and transduction with Ascl1 and Ngn2 | [ | ||
| MAPK/ERK | Inhibited by PD0325901 | Mouse neural progenitor cells → iPSCs | – | [ |
| ROCK | Inhibited by Y-27632 | Mouse fibroblasts → cardiomyocytes | – | [ |
| Human dermal fibroblasts → induced multipotent mesenchymal stem cell–like cells (iMSCs) | With SP600125 (JNK inhibitor), SB202190 (p38 inhibitor), Go 6983 (PKC inhibitor), PD0325901 (ERK1/2 inhibitor), and CHIR99021, with or without growth factors (TGF-β, bFGF, and LIF) | [ | ||
| mTOR | Inhibited by Sox2 | Mouse embryonic fibroblasts → iPSC | – | [ |
Fig. 5Schematic diagram of cell plasticity and differentiation
Fig. 6Heatmap of uterine cell-cell interaction
Fig. 8Hypothesized transdifferentiation of pericytes and endothelial cells to fibroblasts
Fig. 7Hypothesized repair mechanism by stem cell therapy
| Problem or issue | What is already known | What this paper adds |
| IUA causes severe gynecological disorders, but the prevention strategies and treatments have been unsatisfactory and improvements are limited. Current knowledge on IUA pathogenesis was mostly derived from tissue studies without considering the multicellular structures and their orchestration in the endometrial tissue and in-depth mechanistic investigations. Development of stem cell–related therapies is limited. | TGF-β1/SMAD pathway is most likely to play a central role in IUA pathogenesis while other candidates were listed. Molecules and signaling pathways associated with cell plasticity were also listed. Stem cell–related therapies were proved to be effective in animal and clinical studies. | Analyses of uterine cell heterogeneity and cellular expression profile indicate that the previous research methods on IUA pathogenesis may miss important details. Analysis of cell-cell interaction suggested that injured endometrial cells may communicate with other cells via endothelial system and fibroblasts could be the first few to respond and finally lead to fibrosis. The repairing effects of stem cell–derived vesicles are worth exploration and the list of candidates are summarized in this review. |